Nephros (River Edge, NJ), a medical device company that develops and sells high-performance liquid purification ultrafilters and a hemodiafiltration (HDF) system for use with a hemodialysis machine, reported in its first quarter 2016 results that it had gained “510(k) clearance on two additional products and successfully completed the software upgrade and additional training development for our H2H (company brand) modules needed to expand our hemodiafiltration footprint.” Nephros said the company will aim for positive cash flow from its products in the coming months.
The firm’s SSUmini, launched in March 2016, is aimed at dialysis clinics that need an economical solution for a polish filter (to remove small particulate material or dissolved material) for smaller, portable reverse-osmosis systems that need hemodialysis-quality water. The SSUmini also provides hemodialysis-quality bicarbonate concentrate for dialysis clinics with centralized bicarbonate systems.
Nephros announced that EndoPur™ will become the brand name for all of its ultrafiltration products for dialysis water and bicarbonate concentrate, including the SSUmini, the DSU-D, the SSU-D, and the 10” cartridge platform.
For the quarter that ended March 31, 2016, total revenues were approximately $590,000 and operating expenses were approximately $1.1 million, compared to approximately $544,000 and $1,088,000 for the quarter ended March 31, 2015.
